Aurora Cannabis Launches New IndiMed TEMPO 22 Medical Products in Australia

Aurora Expands Medical Cannabis Offerings in Australia

Aurora Cannabis Inc., a leading name in the global medical cannabis sector, has made headlines with the launch of its new medical cannabis product, IndiMed TEMPO 22, available through its subsidiary, MedReleaf Australia. As of June 5, 2025, this development marks an important stride for the company, affirming its commitment to meeting the diverse needs of patients across Australia.

The IndiMed TEMPO 22 line introduces two distinct cultivars, both boasting a substantial 22% THC concentration, ensuring quality and efficacy in treatment. The two new offerings are:
1. IndiMed TEMPO 22 | Lemon Laser - A Sativa variant with 22% THC and less than 1% CBD, available in a 15g pack.
2. IndiMed TEMPO 22 | Pickled Petrol - An Indica variant, also containing 22% THC and less than 1% CBD, packaged similarly.

According to Andre Jerome, Executive Vice President of Global Business Development at Aurora, this expansion within the value segment of the Australian market highlights a responsive approach to increasingly diversified patient demands for high-quality medical cannabis. "We are proud to offer innovative solutions that not only meet local needs but also reflect our global dedication to excellence," Jerome articulated in a recent statement.

Since its inception, the IndiMed brand has earned a reputation as one of the most prescribed lines of medical cannabis in Australia, and this latest product launch aims to bolster its appeal among healthcare prescribers and patients alike. Aurora's dedication to providing diverse and accessible medical cannabis options has further solidified its standing as a market leader in Australia.

MedReleaf Australia emphasizes its adherence to TGA-GMP standards, ensuring that all products meet rigorous quality and safety regulations. This commitment not only enhances consumer trust but also supports the company’s mission to expand patient access to effective cannabis treatments. Healthcare professionals seeking more information about the new offerings can reach out to MedReleaf’s clinical support team or visit the official website at www.medreleafaustralia.com.au.

Aurora Cannabis has established a robust presence across multiple markets, including Canada, Europe, and New Zealand, often focusing on both medical and consumer cannabis sectors. Their diverse portfolio comprises several brands, launching various product lines reflecting their commitment to innovation and customer satisfaction. The company operates under the principles of science and quality, with its brands leading in both the medical and recreational markets.

As Aurora continues to innovate and expand its footprint in the medical cannabis field, it remains dedicated to enhancing the quality of life for individuals using cannabis as part of their health and wellness regimen. The launch of IndiMed TEMPO 22 is just one of many steps in their ongoing journey to serve patients and customers worldwide effectively. By ensuring high-quality options that promote accessibility, Aurora aims to remain a trusted provider in the ever-evolving landscape of medical cannabis.

To learn more about Aurora Cannabis, you can explore their website at www.auroramj.com, where you can find detailed information about their various offerings, including the newly launched IndiMed TEMPO 22 products.

In conclusion, as this exciting new product line becomes available, the prospect of improving patient experiences with medical cannabis becomes even brighter. Aurora's expansion into the Australian market not only highlights its commitment to innovation but also underscores its role as a crucial player in the global cannabis industry, continually striving to embrace new opportunities and meet the needs of patients around the world.